Feb 20, 2026 08:50AM
Feb 20, 2026 08:50AM
Feb 11, 2026 08:35AM
Feb 11, 2026 08:35AM
Jan 14, 2026 09:15AM
Dec 9, 2025 07:02AM
Dec 9, 2025 07:00AM Senti Bio reports positive trial results for cancer therapy SENTI-202
Dec 9, 2025 07:00AM
Dec 9, 2025 07:00AM
Nov 3, 2025 09:05AM
Aug 7, 2025 08:05AM
Aug 7, 2025 08:05AM
Aug 5, 2025 08:30AM
Aug 5, 2025 08:30AM Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Jun 30, 2025 09:15AM
Jun 18, 2025 07:01AM
Jun 18, 2025 07:00AM
May 9, 2024 04:05PM
Mar 21, 2024 04:05PM
Jan 5, 2024 04:05PM
Jan 5, 2024 04:05PM Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
Dec 22, 2023 06:30AM
Dec 22, 2023 06:30AM
Nov 13, 2023 04:15PM
Aug 11, 2023 08:35AM
May 20, 2023 08:05AM
May 2, 2023 04:45PM
May 2, 2023 04:45PM Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
Mar 22, 2023 05:09PM
Jan 27, 2023 08:00AM
Jan 27, 2023 08:00AM
Jan 27, 2023 08:00AM
Nov 10, 2022 07:55AM
Nov 10, 2022 07:55AM
Jun 9, 2022 07:33AM Senti Bio (SNTI) Debuts as Publicly Traded Company
Jun 9, 2022 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All